Septerna (NASDAQ:SEPN) Downgraded to Equal Weight Rating by Wells Fargo & Company

Septerna (NASDAQ:SEPN - Get Free Report) was downgraded by equities research analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They presently have a $14.00 price objective on the stock, down from their previous price objective of $43.00. Wells Fargo & Company's price target suggests a potential upside of 141.38% from the company's previous close.

Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. started coverage on shares of Septerna in a report on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price objective for the company. TD Cowen started coverage on shares of Septerna in a report on Tuesday, November 19th. They set a "buy" rating for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th.

Septerna Trading Down 1.5 %

Shares of SEPN stock traded down $0.09 during trading hours on Tuesday, reaching $5.80. 1,158,707 shares of the stock were exchanged, compared to its average volume of 586,476. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99. The stock's 50-day moving average is $17.78.

Insider Activity

In other Septerna news, CFO Gil M. Labrucherie purchased 5,000 shares of Septerna stock in a transaction dated Friday, February 21st. The stock was acquired at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at $175,500. This trade represents a 20.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On Septerna

Several large investors have recently modified their holdings of the business. Woodline Partners LP bought a new stake in shares of Septerna in the 4th quarter valued at about $6,870,000. Zimmer Partners LP purchased a new position in shares of Septerna in the 4th quarter worth approximately $229,000. Soleus Capital Management L.P. purchased a new position in shares of Septerna in the 4th quarter worth approximately $15,467,000. Nuveen Asset Management LLC purchased a new position in shares of Septerna in the 4th quarter worth approximately $549,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Septerna in the 4th quarter worth approximately $278,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.